A patient with Crohn's disease of the colon developed severe abdominal pain after salicylicazosulfapyridine and after disodium azodisalicylate therapy. Raised serum and urinary amylase levels were found after disodium azodisalicylate. Rechallenge with disodium azodisalicylate caused a recurrence of the pain and of the elevated amylase levels. The time course of these episodes was compatible with 5-aminosalicylate-induced pancreatitis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Rapid and Reliable Absorbance Assay to Identify Drug-Drug Interactions with Thiopurine Drugs.
Metabolites
December 2024
Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, USA.
Background: Thiopurine methyltransferase (TPMT) plays a crucial role in the detoxification of thiopurine drugs, including the antimetabolites azathioprine and 6-mercaptopurine (6-MP) used to treat autoimmune diseases and various cancers. These drugs interfere with DNA synthesis by inhibiting the production of purine-containing nucleotides, leading to the death of rapidly dividing cells. TPMT inactivates thiopurine drugs by methylating at the thiol group.
View Article and Find Full Text PDFAn Innovative Inhibitor with a New Chemical Moiety Aimed at Biliverdin IXβ Reductase for Thrombocytopenia and Resilient against Cellular Degradation.
Pharmaceutics
August 2024
Korea Basic Science Institute, 162 Yeongudanji-Ro, Ochang-Eup, Cheongju-Si 28119, Republic of Korea.
Article Synopsis
- Biliverdin IXβ reductase (BLVRB) is a key target for treating thrombocytopenia, as it relates to the management of reactive oxygen species (ROS).
- Olsalazine (OSA) has been identified as a strong inhibitor of BLVRB but is unstable due to degradation by gut bacteria enzymes, which complicates its use.
- To address this, a new compound called olsalkene (OSK) was developed, which maintains OSA’s effectiveness while being more stable and can inhibit BLVRB in different conditions, paving the way for new research on its role in blood disorders.
Refractory Crohn's Disease Responsive to Dietary Therapy: A Case Report.
Cureus
May 2024
Internal Medicine, University of North Carolina Hospitals, Chapel Hill, USA.
Article Synopsis
- Crohn's disease is an inflammatory bowel disease that often starts in young adulthood, and while medications are available to manage its symptoms, some patients don't find relief and explore diet modifications as an alternative.
- The underlying issues in Crohn's include uncontrolled inflammation and genetic factors, with certain anti-inflammatory diets potentially lowering gut inflammation and improving symptoms; examples include the IBD-AID and the Crohn's exclusion diet.
- A case study highlighted a patient who experienced treatment-resistant Crohn's despite various medications, leading them to investigate anti-inflammatory diets, suggesting that these diets could be beneficial for those not responding to standard treatments, emphasizing the need for education among healthcare providers and patients.
Discovery of putative inhibitors of human Pkd1 enzyme: Molecular docking, dynamics and simulation, QSAR, and MM/GBSA.
Environ Res
September 2024
International Joint Laboratory on Synthetic Biology and Biomass Biorefinery, Biofuels Institute, School of Emergency Management, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang, 212013, China. Electronic address:
Polycystic kidney disease is the most prevalent hereditary kidney disease globally and is mainly linked to the overexpression of a gene called PKD1. To date, there is no effective treatment available for polycystic kidney disease, and the practicing treatments only provide symptomatic relief. Discovery of the compounds targeting the PKD1 gene by inhibiting its expression under the disease condition could be crucial for effective drug development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!